Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ACE inhibitor drug reduces heart failure in high-risk patients

25.02.2003


The drug ramipril significantly reduced the onset of debilitating and often-fatal heart failure in a large group of high-risk patients, researchers report in today’s rapid access issue of Circulation: Journal of the American Heart Association.



Ramipril, trade-named Altace, is one of a family of high blood pressure medications known as ACE inhibitors. The drugs reduce the risk of death from heart failure – the inability of a weakened or damaged heart to pump enough blood through the body – in people who suffer heart attacks. The American Heart Association estimates that nearly 5 million people in the United States have congestive heart failure.

"This trial extends the benefits of ACE inhibitors beyond what has been previously proven," says lead author Malcolm Arnold, M.D., "It shows, for the first time, that heart failure can be prevented in a broad range of high risk patients."


Researchers found that ramipril reduced the risk of heart failure by 23 percent in patients with cardiovascular disease who still had normal heart pumping function and no previous heart failure. Patients who received the drug also had a lower rate of hospitalization and death because of heart failure.

"The reduction of heart failure in people treated with ramipril was consistent in all major subgroups," says Arnold, professor of medicine, physiology, and pharmacology at the University of Western Ontario and a cardiologist at the London Health Sciences Center in London, Ontario, Canada. "These included patients over 65 years, females, and patients without known hypertension or diabetes." The trial is from the Heart Outcomes Prevention Evaluation (HOPE) study, a randomized trial that followed 9,541 high-risk cardiovascular patients age 55 and older at 267 centers in 19 countries in the Americas and Europe.

In the new analysis, the researchers used data from 9,297 of the HOPE participants who had randomly received either 10 milligrams of ramipril or a placebo daily and were followed for an average of 4.5 years. Their average age was 66 and 73 percent were males. Fifty-three percent had a previous heart attack, 47 percent had a history of hypertension, and 38 percent had diabetes – all risk factors for heart failure.

Researchers defined heart failure as any of the following: poor heart pumping that caused death, or required hospitalization or treatment with ACE inhibitors as determined by a physician, or the appearance of the disease’s typical signs and symptoms. One or more of these components occurred in 951 (10.2 percent) of the participants during the follow-up period.

Ramipril reduced the rate of heart failure by a significant 22 percent in the 8,315 patients who did not suffer a heart attack. Among the 1,029 people who had a heart attack, those taking ramipril had a 13 percent lower rate of heart failure, although this finding did not reach statistical significance, Arnold says.

In addition, patients treated with ramipril whose systolic blood pressure (the upper number in a blood pressure reading) was above the median had a 33 percent reduction in risk of heart failure compared to a 9 percent reduction for those below the median.

In an accompanying editorial, Jennifer V. Linseman, Ph.D., and Michael R. Bristow, M.D., Ph.D., of the University of Colorado Health Sciences Center in Denver, note that for a majority of the participants in this analysis were classified with heart failure if their symptoms were severe enough that they need to be treated with ACE inhibitors.

This is a "softer endpoint that death or hospitalization . . . ." they write. "Therefore results, while still encouraging, should be viewed with some caution."

Taken with previous results from the HOPE study, they say: "these data support the idea that ACE inhibitors exert a measurable cardiovascular-protective effect in a broad range of patients at high-risk of cardiovascular complications, and these effects are additional to and independent of blood pressure lowering."

Arnold’s co-authors are Salim Yusuf, M.D.; James Young, M.D.; James Mathew, M.D.; David Johnstone, M.D.; Alvaro Avezum, M.D.; Eva Lonn, M.D.; Janice Pogue; and Jackie Bosch on behalf of the HOPE investigators.


CONTACT: For journal copies only, please call: 214-706-1396

For other information, call:
Carole Bullock: 214-706-1279
Bridgette McNeill: 214-706-1135

Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>